BMS Gets US Approval Of Ozanimod For Relapsing MS, But Launch Delayed

Zeposia, one of three Celgene candidates central to last year’s merger with BMS, obtains US FDA approval in relapsing MS. BMS, however, will delay the launch due to the COVID-19 pandemic.